|Awarded On||November 16, 2016|
|Title||Discovery of antibody-drug conjugates targeting a receptor broadly expressed in solid tumors|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Qingyun Liu|
|Cancer Sites||Breast, Colorectal, Ovary|
Antibody-drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specificity of mAbs against their antigen targets with highly potent cytotoxic drugs, resulting in “armed” mAbs that deliver the payload (drug) to tumor cells with enriched levels of the antibody target. As antibody engineering and linker-payload optimization are becoming more and more mature, the discovery and development of new ADCs is increasingly dependent on the identification and validation new targets that are suitable to this approach. LGR4 is a seven transmembrane domain recept...